New anticoagulants: Pharmacology and clinical studies

Wiener Medizinische Wochenschrift

Volumn 161, Issue 3-4, 2011, Pages 54-57

  Samama, Charles Marc ^a  

^a HÔTEL DIEU   (France)

Author keywords

Apixaban; Atrial fibrillation; Bleeding; Dabigatran; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; ELIQUIS; ENOXAPARIN; LEPIRUDIN; NEW DRUG; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ARTICLE; BLEEDING; CLINICAL STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; ORTHOPEDICS; PHARMACOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); THROMBOSIS; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; FACTOR XA; HEMORRHAGE; HUMANS; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; PROTHROMBIN; PYRAZOLES; PYRIDONES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 79953296008     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-011-0875-9     Document Type: Article

References (18)

1. TE Warkentin A Greinacher A Koster AM Lincoff Physicians ACoC 2008 Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 340S 380S 18574270 10.1378/chest.08-0677 1:CAS:528: DC%2BD1cXptVKhsro%3D (Pubitemid 351892970)
2. JI Weitz 2010 New oral anticoagulants in development Thromb Haemost 103 62 70 20062934 1:CAS:528:DC%2BC3cXhs1Cqu70%3D
3. MR Lassen W Ageno LC Borris, et al. 2008 Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2776 2786 18579812 10.1056/NEJMoa076016 1:CAS:528:DC%2BD1cXnvFagt70%3D (Pubitemid 351930852)
4. BI Eriksson LC Borris RJ Friedman, et al. 2008 Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2765 2775 18579811 10.1056/NEJMoa0800374 1:CAS:528:DC%2BD1cXnvFahtbo%3D (Pubitemid 351930851)
5. Xu Q. Xarelto (Rivaroxaban). FDA Cardiovascular and Renal Drugs Advisory Committee Meeting March 19, 2009
6. MM Samama J-L Martinoli L LeFlem, et al. 2010 Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 103 815 825 20135059 1:CAS:528:DC%2BC3cXls1ansro%3D
7. MR Lassen GE Raskob A Gallus G Pineo D Chen RJ Portman 2009 Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 594 604 19657123 10.1056/NEJMoa0810773 1:CAS:528:DC%2BD1MXps1Kitrc%3D
8. MR Lassen GE Raskob A Gallus, et al. 2010 Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 807 815 20206776 10.1016/S0140-6736(09)62125-5 1:CAS:528:DC%2BC3cXivFegsrg%3D
9. MR Lassen A Gallus G Rakob G Pineo D Chen L Ramirez 2010 Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement N Eng J Med 363 2487 2498 10.1056/NEJMoa1006885 1:CAS:528:DC%2BC3cXhs1WhsL%2FJ
10. BI Eriksson OE Dahl HR Büller, et al. 2005 A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial J Thromb Haemost 3 103 111 15634273 10.1111/j.1538-7836.2004.01100.x 1:CAS:528:DC%2BD2MXhtlWiurs%3D (Pubitemid 41647122)
11. BI Eriksson OE Dahl N Rosencher, et al. 2007 Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 949 956 17869635 10.1016/S0140-6736(07)61445-7 1:CAS:528:DC%2BD2sXhtVeqsL7F (Pubitemid 47393577)
12. BI Eriksson OE Dahl N Rosencher, et al. 2007 Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2178 2185 17764540 10.1111/j.1538-7836.2007.02748.x 1:CAS:528:DC%2BD2sXhsVSis7fM (Pubitemid 47617868)
13. The RE-MOBILIZE Writing Committee 2009 The oral thrombin inhibitor dabigatran etexilate vs. the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 1 9
14. SJ Connolly MD Ezekowitz S Yusuf, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
15. S Schulman C Kearon AK Kakkar, et al. 2009 Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2342 2352 19966341 10.1056/NEJMoa0906598 1:CAS:528:DC%2BD1MXhsFGqsrbN
16. J van Ryn J Stangier S Haertter, et al. 2010 Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 1106 1127
17. N Rosencher P Zufferey C-M Samama 2010 Definition of major bleeding in surgery: an anaesthesiologist's point of view J Thromb Haemost 8 1442 1443 20345706 10.1111/j.1538-7836.2010.03874.x 1:STN:280:DC%2BC3cjnsF2msw%3D%3D
18. JI Weitz J Hirsh MM Samama 2008 New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 234S 256S 18574267 10.1378/chest.08-0673 1:CAS:528: DC%2BD1cXptVKiu7Y%3D (Pubitemid 351892968)